Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Net Cash Flow (2016 - 2025)

Celldex Therapeutics (CLDX) has 16 years of Net Cash Flow data on record, last reported at -$7.2 million in Q4 2025.

  • For Q4 2025, Net Cash Flow rose 10.84% year-over-year to -$7.2 million; the TTM value through Dec 2025 reached $515000.0, up 107.97%, while the annual FY2025 figure was $515000.0, 107.97% up from the prior year.
  • Net Cash Flow reached -$7.2 million in Q4 2025 per CLDX's latest filing, down from $13.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $80.3 million in Q1 2024 and bottomed at -$72.3 million in Q2 2024.
  • Average Net Cash Flow over 5 years is -$748250.0, with a median of -$6.7 million recorded in 2023.
  • Peak YoY movement for Net Cash Flow: plummeted 933.3% in 2023, then soared 305.38% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at -$33.0 million in 2021, then skyrocketed by 132.83% to $10.8 million in 2022, then grew by 26.13% to $13.7 million in 2023, then plummeted by 158.79% to -$8.0 million in 2024, then grew by 10.84% to -$7.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Cash Flow were -$7.2 million in Q4 2025, $13.0 million in Q3 2025, and $5.9 million in Q2 2025.